"At this point in time when the PSA has been shown to be ineffective in identifying clinically significant prostate cancer, Health Discovery Corporation's recent biomarker discovery creating a genomic based test that separates grade 4/5 prostate cancer, the most malignant and clinically significant type of prostate cancer from BPH (benign prostatic hypertrophy) and normal prostate with a very high degree of accuracy is an exciting and outstanding accomplishment"
Dr. Thomas A. Stamey
Professor & Founding Chairman
Department of Urology
Stanford University Medical Center

"This impressive new gene discovery will give us access to a new set of biomarkers in advanced prostate cancer. We intend to use these findings to develop new diagnostic approaches for prostate cancer diagnosis and improve the clinical management of these patients."
Dr. Herbert Fritsche
Professor and Chief of Clinical Chemistry
M.D. Anderson Cancer Center

Health Discovery Corporation has identified and patent protected a subset of genes which indicate disease progression from less malignant to more malignant forms of prostate cancer. Such genes separate grade 4/5 prostate cancer, the most malignant form of prostate cancer, from less malignant grades of prostate cancer and normal tissues with a high degree of accuracy.

200,000 men in the United States were diagnosed with prostate cancer and 40,000 men died from it in 2004. It is the second-leading cause of cancer death in men, after lung cancer.

More than 1 million men a year undergo biopsies of the prostate gland after a cancer-screening test reveals moderately elevated levels of prostate specific antigen (PSA) in the blood. The problem is that only one in four of these biopsies finds evidence of cancer. Experts estimate that 750,000 of the 1 million biopsies performed each year are unnecessary. The most common reason for an elevated PSA is benign prostate enlargement, which is normal in older men. The PSA can be raised by benign prostatic hyperplasia, biopsy of the prostate, transurethral prostatectomy, acute urinary retention, acute prostatitis, and ejaculation.